PEDIATRICS Vol. 81 No. 2 February 1988, pp. 272-276
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peters, C.
Right arrow Articles by Zinkham, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peters, C.
Right arrow Articles by Zinkham, W. H.

Homozygous Protein C Deficiency: Observations on the Nature of the Molecular Abnormality and the Effectiveness of Warfarin Therapy

Charles Peters MD1, James F. Casella MD1, Richard A. Marlar PhD1, Robert R. Montgomery MD1, and William H. Zinkham MD1

1 From the Department of Pediatrics, Division of Hematology, The Johns Hopkins School of Medicine, Baltimore, and the Thrombosis Research Laboratory, Blood Center of Southeastern Wisconsin, Milwaukee

An infant with severe homozygous protein C deficiency was brought to medical attention because of purpura fulminans and severe bilateral vitreous hemorrhages in the neonatal period. Infusions of fresh frozen plasma were given for 8 months. On two occasions, attempts to decrease the frequency of fresh frozen plasma infusions to less than twice a day led to episodes of microangiopathic hemolysis, fibrinolysis, and acute renal failure. Infarction of skin and subcutaneous tissues did not recur. Both episodes were controlled after reinstitution of fresh frozen plasma. Complications of therapy with fresh frozen plasma included hyperproteinemia and hypertension. Warfarin therapy was instituted when the baby was 8 months of age, followed by a gradual withdrawal of fresh frozen plasma therapy. The dose of warfarin required to maintain the prothrombin time in a range of 1.8 to 2.2 times normal varied considerably during short periods, a phenomenon that may have been due to several factors: hypercatabolism of the drug with prolonged administration, abnormality of liver function, variation in levels of serum albumin, fluctuations in drug dosage secondary to oral administration, and variations in dietary vitamin K. Protein C determinations by immunologic and functional assays consistently showed detectable but reduced protein C antigen levels with undetectable activity levels, suggesting that a dysproteinemia rather than a deficiency of synthesis is responsible for the child's coagulopathy.

Key Words: protein C deficiency • warfarin • vitamin K-dependent factors • hypercoagulability • disseminated intravascular coagulation

Submitted on November 17, 1986
Accepted on February 27, 1987




This article has been cited by other articles:


Home page
 ChestHome page
P. Monagle, A. Chan, P. Massicotte, E. Chalmers, and A. D. Michelson
Antithrombotic Therapy in Children*: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 645S - 687S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Monagle, A. D. Michelson, E. Bovill, and M. Andrew
Antithrombotic Therapy in Children
Chest, January 1, 2001; 119(1_suppl): 344S - 370S.
[Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
A. G. M. van den Belt, M. H. Prins, M. V. Huisman, and J. Hirsh
Familial Thrombophilia: A Review Analysis
Clinical and Applied Thrombosis/Hemostasis, October 1, 1996; 2(4): 227 - 236.
[Abstract] [PDF]